Teaching old drugs new tricks to stop malaria invasion in its tracks by Vasant Muralidharan & Boris Striepen
Muralidharan and Striepen BMC Biology  (2015) 13:72 
DOI 10.1186/s12915-015-0185-6COMMENTARY Open AccessTeaching old drugs new tricks to stop
malaria invasion in its tracks
Vasant Muralidharan* and Boris StriepenAbstract
Malaria is a common and life-threatening disease
endemic in large parts of the world. The emergence
of antimalarial drug resistance is threatening disease-
control measures that depend heavily on treatment of
clinical malaria. The intracellular malaria parasite is
particularly vulnerable during its brief extracellular
stage of the life cycle. Wilson et al. describe a screen
targeting these extracellular parasite stages and make
the surprising discovery that clinically used macrolide
antibiotics are potent inhibitors of parasite invasion
into erythrocytes.
See research article:
http://www.biomedcentral.com/1741-7007/13/52K13 kelch propeller domain protein have been associ-Commentary
Malaria is a dangerous and common disease that stalks
most of the tropical and sub-tropical parts of the world,
home to about 3.5 billion people. The disease is caused
by single-celled obligate intracellular eukaryotic parasites
of the genus Plasmodium and is associated with signifi-
cant mortality in the case of one species, Plasmodium
falciparum. The lifecycle of Plasmodium is complicated,
with sexual growth within mosquitos and asexual growth
within vertebrate hosts, including humans. Transmission
depends upon the bite of an infected mosquito. Thus,
control of malaria relies in part on insecticide-treated
bed nets to prevent mosquitos from feeding. Another
mainstay of malaria control are antimalarials that treat
clinical disease and are used in preventative or targeted
mass drug administration for specific populations. These
disease control mechanisms have resulted in a signifi-
cant reduction in the burden of malaria. Over the past
decade, mortality from malaria has been reduced to* Correspondence: vasant@uga.edu
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stated.600,000 deaths per year from a peak of nearly 1.1 million
deaths per year [1], a 45 % decrease attributed to the use
of bed nets and to the antimalarial drug artemisinin [1].Resistance at the front line
Artemisinin combination therapies, which are combina-
tions of potent but short-lived artemisinin with long act-
ing partners, have been very successful in combating
malaria. However, this progress is under grave threat be-
cause of emergence of artemisinin-resistant P. falcip-
arum [2]. Clinical resistance to artemisinin is not readily
spotted in short-term parasite growth assays, but reveals
itself in the peculiar ability of the parasites to ‘hibernate’
in the presence of drug, ready to rebound as soon as
treatment is discontinued. The hallmark of resistance is
a reduced rate of parasite clearance. Mutations in the
ated with this phenotype through genetic analysis of re-
sistant parasites selected deliberately in the laboratory
and collected from natural infection in the field [3].
While clearly associated with the mechanism of resist-
ance, this protein is likely not the direct molecular target
of the drug. Proteins that associate with the kelch pro-
tein are among the candidates [4], but the case is far
from closed at this point. Regardless of mechanism, to
preserve the gains against clinical malaria in the face of
the parasite’s remarkable ability to develop drug resist-
ance it is essential that we keep step with a deep portfo-
lio of new drugs ready to take over when inevitable
resistance breaks through.Common antibiotics as invasion-inhibitory
anti-malarials
In research recently reported in BMC Biology Wilson
and colleagues [5] seek to add to the anti-malarial port-
folio with a screen for inhibitors of parasite host cell inva-
sion. Surprisingly, among the best compounds to emerge
from this effort are well known macrolide antibiotics, in-
cluding azithromycin, erythrocymicin, and roxithromycin,
that were found to inhibit invasion of red blood cells byess This article is distributed under the terms of the Creative Commons
ativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution,
u give appropriate credit to the original author(s) and the source, provide a link
e if changes were made. The Creative Commons Public Domain Dedication
ain/zero/1.0/) applies to the data made available in this article, unless otherwise
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had the most potent effect.
The use of antibiotics is not new in the treatment of
malaria [6]; in particular, inhibitors of bacterial protein
translation are known to kill P. falciparum. This initially
may be unexpected for a eukaryotic pathogen, but the
discovery of the parasite plastid or apicoplast revealed a
possible target [7]. Like all plastids, this parasite organ-
elle evolved form cyanobacterial ancestors and is suscep-
tible to inhibition of its prokaryotic ribosomes [8]. The
apicoplast is an essential organelle required for the pro-
duction of several important metabolites [9]. However,
inhibition of protein translation in the apicoplast leads
to a ‘delayed death’ [8]. This peculiar feature of antibiotic
action on parasite growth and the resulting lag phase in
the onset of efficacy may limit the usefulness of these
drugs against acute infection.
So did Wilson et al. rediscover plastid inhibitory activ-
ity of macrolides or are they on the trail of something
new? In a set of time-limited drug exposure experiments
they convincingly demonstrate a fast invasion inhibitory
activity that is independent of and in addition to the
slow plastid effect of azithromycin (Fig. 1) [5]. Observing
this phenomenon was made possible by a recently devel-
oped method for isolation of viable invasive stages of P.
falciparum [10]. Incubating purified invasive stages with
red blood cells for short periods followed by drug wash-
out resulted in almost complete loss of parasite invasion
[5]. On the other hand, similar incubation of post-
invasion life stages with azithromycin had no effect on
parasite growth [5]. The two-target hypothesis was also
supported by medicinal chemistry and structure function
analysis: some macrolide analogues showed increased
activity against merozoite invasion while their anti-
apicoplast activity remained unchanged from that of azi-
thromycin [5].Fig. 1. Two independent targets for macrolide antibiotics in Plasmodium fa
(green). Loss of translation in the plastid ultimately starves the parasite (grey
(IPP). Wilson et al. describe a second mode of action in which azithromycin
blood cells (RBC, red). This effect is much faster, but requires higher concenThe promise and problems of antibiotics as dual
action anti-malarials
A fast acting antibiotic could be very attractive for mal-
aria therapy. Antibiotics are well-worn tools of the med-
ical trade and their established clinical profile, good
safety record, and moderate cost could fast track new
treatments. Relatively high concentrations of azithromy-
cin are required to block invasion, but these may not be
as easily or safely reached in vivo [5]. Conceptually, fo-
cusing on invasion narrows the opportunity for chemical
interference to a very important but also very brief time
period. Invasion takes place in about 120 seconds of the
48 hour growth cycle. Lastly, Plasmodium and the re-
lated apicomplexan parasite Toxoplasma gondii have
demonstrated significant flexibility and quickly adapt to
experimental insults directed at their invasion machinery
[11]. This includes the genetic deletion or chemical re-
moval of ligands and adapters from the parasite and the
host, revealing a buffer of redundancy around the essen-
tial event of invasion. Insight into the mechanism of
action and the potential redundancy of the specific mo-
lecular target will be crucial to understand whether azi-
thromycin is a bullet that parasite invasion ultimately
can or cannot dodge.
How do antibiotics block invasion?
Forward genetics would be the weapon of choice to at-
tack the mode of action of the antibiotic invasion block.
The malaria parasite is haploid and isolation of resist-
ance mutants followed by genetic mapping has been a
highly successful way to define drug targets [12]. In a
decade long campaign, the Wellems laboratory at the
NIH pioneered this genetic mapping method to discover
the mutations responsible for chloroquine resistance.
The advent of low cost whole genome sequencing has
been truly transformative, yielding high-density singlelciparum. Azithromycin inhibits protein synthesis in the apicoplast
) for the essential isoprenoid precursor isopentenyl-pyrophosphate
blocks an early step in the process used by the parasite to invade red
trations of drug
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and resistant lines with reasonable investment. At the
same time, transfection experiments to directly test
whether a mutation is the cause of resistance have be-
come more and more powerful. CRISPR/Cas9 systems
now allow marker-free genome editing to rigorously val-
idate such mutations. Unfortunately, the dual-mode of
action of azithromycin makes the isolation and analysis
of invasion-specific azithromycin resistance mutants a
non-trivial undertaking.
The target of azithromycin appears broadly conserved
as the drug also inhibits invasion of other apicomplexan
species into their respective host cells [5]. Azithromycin-
treated parasites bind to but then let go of their host
without productive invasion. In the presence of drug,
they appear unable to form a moving junction, a unique
parasite induced structure linking host and parasite
membranes and used by the parasite to propel itself into
the red blood cell. There are several possible ways by
which azithromycin might inhibit parasite invasion, an
essential process required for parasite propagation and
spread. Azithromycin may interfere with vital ligand-
receptor interactions. Disruption of parasite invasion in
an analogous fashion by targeting the host protein basi-
gin with recombinant chimeric antibodies cures estab-
lished infections in a humanized mouse model [13]. As
invasion relies on secretion and delivery of parasite fac-
tors to the host this may be another potential target.
Interference with the complex regulatory machinery of
the invasion process provides additional candidates. A
new stem cell-derived model to dissect Plasmodium in-
vasion opens the door to manipulation of both host and
parasite components at a level previously not attainable
[14]. By the same token, using azithromycin as a chem-
ical biology tool compound could prove to be a highly
complementary approach to understand not only its
mode of action but the invasion process in general.
Overall, this study should reignite interest in antibi-
otics as anti-malaria drugs and specifically spur future
studies into macrolides and invasion. Utilizing these an-
tibiotics in combination with artemisinin may even slow
the spread of artemisinin resistance — and in this con-
text their dual activity may be an asset. Since macrolides
are already in clinical use, there is a wealth of informa-
tion and experience in their use, adding to the list of ur-
gently needed drug candidates at a time when the
frontline antimalarial, artemisinin, is losing its efficacy.Acknowledgements
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